MicroPort® CardioFlow Attends Fourth China Valve (Hangzhou) Meeting

Hangzhou, China – On March 30, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") attended the Fourth China Valve (Hangzhou) Meeting hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine.
Since its first use in 2002, transcatheter aortic valve replacement ("TAVR") has revolutionized the cardiovascular industry. In this meeting, domestic and overseas experts conducted in-depth discussion on the current situation and future development of VAVR technologies. Academician Junbo Ge of Zhongshan Hospital of Fudan University introduced the design rationale of VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®") and released the one-year follow-up result of VitaFlow® which showed that the occurrence of all-cause mortality is as low as 2.7%, and there is no major stroke. All of the patients reported good hemodynamic function, no moderate or severe PVL, and significant improvement in NYHA class (97% NYHA≤Ⅱ). The treatment outcomes of patients with BAV stenosis are similar with those who with tricuspid valve stenosis. The one-year clinical data of VitaFlow® is competitive compared to similar products.
VitaFlow® is consisted of transcatheter aortic valve, delivery system, balloon catheter and introducer set. Academician Junbo Ge highly recognized their safe and effective clinical outcome as well as easy operation in his report. VitaFlow® adopts innovative design with inner and outer skirts, which effectively reduce the occurrence of paravalvular leak. In addition, large cell design leaves space for interventional treatment of coronary artery. Its delivery system with motorized handle enables the physician to deploy the valve while controlling the guide wire, improving the overall efficiency.
During the meeting, Academician Ge also gave a report on the future development of VAVR. He said, the ultimate goal of TAVR is All Comes TAVR, which means the technique will allow anyone who suffers from aortic valvular diseases and needs medical treatment to receive TAVR, no matter how risky the disease is, how the anatomy is, and how old the patient is. In the recent 10 years, TAVR technologies have been experiencing fast development, and the new generation aortic valve has caught wide attention from the industry. In this meeting, several professionals visited MicroPort® CardioFlow booth and showed great interest in VitaFlow® and its promising future development.